BioStem Technologies, Inc.
BioStem Technologies, Inc.
Your view on BSEM
Overview
What the company does, where it operates, and who runs it.
About BioStem Technologies, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jason V. Matuszewski
- Headquarters
- 2836 Center Port Circle, Pompano Beach, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jason V. Matuszewski
- Headquarters
- 2836 Center Port Circle, Pompano Beach, FL, US
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally.
The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BioStem Technologies, Inc., and the rating behind it. BSEM last traded at $4.31; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BioStem Technologies, Inc.. Starting points for BioStem Technologies, Inc.: EPS -$1.63, beta 0.26 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BioStem Technologies, Inc.. BioStem Technologies, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BioStem Technologies, Inc.. Trailing twelve-month EPS for BioStem Technologies, Inc. stands at -$1.63. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BioStem Technologies, Inc.. BioStem Technologies, Inc. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BioStem Technologies, Inc. valued side by side against its closest peers. BioStem Technologies, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BioStem Technologies, Inc., and how their positions are changing. At a $73.2M market value, institutional positions materially move BioStem Technologies, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BioStem Technologies, Inc. executives and directors. Shares of BioStem Technologies, Inc. have traded between $3.09 and $15.74 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BioStem Technologies, Inc.. BioStem Technologies, Inc. is a $73.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BioStem Technologies, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BioStem Technologies, Inc.. Coverage tracks BioStem Technologies, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.